Cambridge Consultants spin-out, Evonetix aims to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging field of synthetic biology.
By employing novel techniques the Chesterford Research Park company claims it can advance DNA synthesis to levels not previously seen.
The company was founded in 2015 with the support of Cambridge Consultants Ltd (CCL) and the entrepreneur and co-founder of Amadeus Capital Partners, Hermann Hauser. It is developing a novel method of manufacturing DNA molecules, using a microchip-based array. The resulting economies of scale mean that Evonetix’ technology will be more economical and flexible than the currently available methods, as well as being more comprehensive in its output. Given that DNA is the raw material for the fast-emerging and exciting field of synthetic biology, economical and flexible manufacture is critical.
The Evonetix team, led by CEO Nick McCook (former CEO of Solexa – pioneers of next-generation sequencing that eventually went on to become part of Illumina) currently consists of 15 staff and continued growth will be based on the achievement of key milestones and the necessary funding to deliver them.